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Parkinson's disease (PD) is the most common neurodegenerative disorder of movement
worldwide. To date, only symptomatic treatments are available. Implantation of
collagen-encapsulated human umbilical cord mesenchymal stem cells (hUC-MSCs) is
being developed as a novel therapeutic approach to potentially modify PD progression.
However, implanted collagen scaffolds may induce a host tissue response. To gain
insight into such response, hUC-MSCs were encapsulated into collagen hydrogels and
implanted into the striatum of hemi-Parkinsonian male Sprague–Dawley rats. One or
14 days after implantation, the area of interest was dissected using a cryostat. Total
protein extracts were subjected to tryptic digestion and subsequent LC–MS/MS
analyses for protein expression profiling. Univariate and multivariate analyses were
performed to identify differentially expressed protein profiles with subsequent gene
ontology and pathway analysis for biological interpretation of the data; 2,219 proteins
were identified by MaxQuant at 1% false discovery rate. A high correlation of label-free
quantification (LFQ) protein values between biological replicates (r = .95) was observed.
No significant differences were observed between brains treated with encapsulated
hUC-MSCs compared to appropriate controls. Proteomic data were highly robust and
reproducible, indicating the suitability of this approach to map differential protein
expression caused by the implants. The lack of differences between conditions suggests
that the effects of implantation may be minimal. Alternatively, effects may only have
been focal and/or could have been masked by nonrelevant high-abundant proteins.
For follow-up assessment of local changes, a more accurate dissection technique, such
as laser micro dissection, and analysis method are recommended.
K E YWORD S
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1 | INTRODUCTION
Parkinson's disease (PD) is the second most common neurodegenerative
disease worldwide affecting 1% of people older than age 60 (Kalia &
Lang, 2015). Neural degeneration is associated with the presence of
Lewy bodies, which contain aggregates of the protein α-synuclein. The
prodromal phase of PD features several non-motor symptoms that
persist in later stages. Only in later stages the typical motor symptoms
appear because, by then, 50%–80% of dopaminergic neurons have died
(Braak et al., 2003). Motor symptoms include rigidity, bradykinesia,
and resting tremor (Kalia & Lang, 2015). Current treatments for
PD are symptomatic and target the dopaminergic system using
pharmacotherapy (mainly L-DOPA) or, in later stages of the disease,
deep brain stimulation. However, there is yet no disease-modifying drug
(Lindholm et al., 2016).
Cell therapy emerged as a promising therapeutic treatment for
neurodegenerative diseases such as PD (Venkataramana et al., 2010;
Venkatesh & Sen, 2017; Yasuhara, Kameda, Sasaki, Tajiri, & Date,
2017). Implanted cells could reinnervate and recover functionality of
the disrupted neuronal network and/or release trophic factors and
anti-inflammatory proteins to promote neuronal survival. It has been
reviewed that preclinical and clinical studies showed controversial
effects after cell implantation. Whereas some studies showed
substantial and long-lasting functional benefits, others showed
marginal or no effects and dyskinesia as an undesired side effect
(Towns, 2017; Winkler, Kirik, & Bjorklund, 2005). Several preclinical
studies also reported poor cell survival and poor engraftment after
implantation and, in some cases, migration of the implanted cells to
other areas of the brain (Lee, Choi, Cha, & Hwang, 2015; Steward,
Sharp, & Matsudaira Yee, 2014). Biomaterials appear to be a good
solution to support cells during the first days after implantation, to
protect them from the immune system, and to narrow their effect to
the area of interest. The biomaterial of choice is not a trivial decision.
Biomaterials for brain regeneration need to be biodegradable,
non-immunogenic, have a softness similar to that of the brain tissue,
and control cell behavior, such as adhesion, migration, apoptosis,
proliferation, and differentiation (Sengupta & Heilshorn, 2010; Zhu &
Marchant, 2011). Polyethylene glycol (PEG)-crosslinked collagen
scaffolds are good candidates because of their biocompatibility and
ability to provide a three-dimensional structure that mimics the
natural extracellular matrix (Zhu & Marchant, 2011). As important as
the biomaterial itself is the selected type of cells. Human umbilical
cord mesenchymal stem cells (hUC-MSCs) are birth-associated stem
cells that present unique advantages for use in regenerative medicine.
hUC-MSCs are obtained through non-invasive procedures, rise
fewer ethical concerns because of their non-embryonic origin, and
they are highly available. Moreover, hUC-MSCs, in comparison with
non-birth-associated stem cells, present higher proliferative capacity,
higher life span, higher differentiation potential, do not induce
teratomas, harbor strong immunomodulatory capacities, and express
genes involved in neuronal development (Castro-Manrreza &
Montesinos, 2015; El Omar et al., 2014; Hass, Kasper, Bohm, &
Jacobs, 2011). Noteworthy, they do not express HLA-DR receptors
and have a low expression level of HLA-ABC, suggesting that
these cells could be good candidates for allogeneic cell therapy
(El Omar et al., 2014).
To accurately assess the efficacy and safety of collagen-
encapsulated hUC-MSCs as a therapy for PD, it is important to
investigate the host tissue response following implantation. To our
knowledge, past studies on cell therapy mainly focused on analyzing
specific markers of inflammation (microgliosis and astrogliosis), cell
survival, and cell reinnervation (Hoban et al., 2013; Moriarty, Cabre,
Alamilla, Pandit, & Dowd, 2019; Moriarty, Pandit, & Dowd, 2017). We
considered it important to deepen the knowledge of host tissue
response, in which we focused on proteins as the active mediators of
biological response. We addressed this using shotgun proteomics, a
mass spectrometry-based approach that allows for large-scale
analysis of proteins in a given tissue at a given state. Thus, we aimed to
investigate the host tissue response at a proteomic level of the
6-hydroxydopamine (6-OHDA) rat model of PD following implantation
of collagen-encapsulated hUC-MSCs. We hypothesized that 24 h after
implantation, markers of gliosis and inflammation could be identified,
but that they would normalize over time and then neurotrophic and
metabolic changes would occur. We aimed to obtain novel insights
into therapeutic mechanisms of collagen-encapsulated hUC-MSCs,
which will allow us to establish changes needed in the collagen
hydrogel composition to improve its safety and therapeutic efficacy.
2 | METHODS
2.1 | Animals
All experiments involving the use of animals were carried out in the
National University of Ireland, Galway, in accordance with relevant
guidelines and regulations, completed under license by the Irish
Department of Health and Children and the Irish Health Products
Regulatory Authority, performed in compliance with the European
Union Directive 2010/63/EU and S. I No. 543 of 2012, and approved
by the Animal Care and Research Ethics Committee at the National
University of Ireland, Galway. Male Sprague–Dawley rats, weighing
200–225 g on arrival, were obtained from Charles River, UK. Animals
(n = 40) were housed in groups of four per cage, on a 12/12-h light/
dark cycle, at 19–23 C, with relative humidity levels maintained
between 40% and 70%. For the duration of the experiment, animals
were allowed food and water ad libitum.
2.2 | Fabrication of cross-linked Type I bovine
collagen hydrogels and hUC-MSCs encapsulation
Collagen hydrogel production was performed as previously described
elsewhere (Moriarty et al., 2017; Moriarty et al., 2019). Briefly, all
components were maintained on ice to prevent gelation. For a final
volume of 200 μl, 133.4 μl of 2-mg/ml Type I collagen (Collagen
Solutions, Galway, Ireland) was mixed with 10 μl of 10× phosphate
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buffered saline (PBS) and neutralized with 1.6 μl of 1-M NaOH to reach
a pH 7. Then 12.5 μl of poly (ethylene glycol) ether tetrasuccinimidyl
glutarate (4S-StarPEG; 4 mg/ml; JenKemTechnology, Plano, Texas, USA)
diluted in 1× PBS was added, and the solution was thoroughly mixed.
Finally, 10 μl of hUC-MSCs (Orbsen Therapeutics, Galway, Ireland;
Passage 3) suspension was added to the collagen/PBS/cross-linker
solution at a final concentration of 10,000 cells/μl for in vivo studies and
also 2,500 cells/μl for in vitro studies. The cell-seeded collagen hydrogel
was maintained on ice prior to transplantation to prevent gelation.
2.3 | Human umbilical cord mesenchymal stem cells
in vitro analyses
hUC-MSCs were purchased at Orbsen Therapeutics at passage
number 2. hUC-MSCs were cultured in a 6-well plate under hypoxic
conditions (2% O2, 5% CO2) at 37 C with minimum essential medium
alpha (α-MEM; Thermo Fisher Scientific, USA) containing 10% of fetal
bovine serum (Sigma), 1% penicillin streptomycin (Biosciences), and
1 ng/ml of human fibroblast growth factor (hFGF). Media were
changed every other day. At passage number 3, cells were harvested
to proceed with collagen encapsulation. Cells were encapsulated at
either 10,000 or 2,500 hUC-MSCs/μl into 3 μl of collagen hydrogel as
described above. After 5 days, collagen hydrogels were degraded for
30 min at 37 C with collagenases from Clostridium histolyticum
(C2674-100MG, Sigma-Aldrich; 0.5-mg collagenases/ml of 1× PBS
containing CaCl2). Cell viability was assessed by using the trypan blue
exclusion test.
2.4 | 6-OHDA lesions and transplantation
All surgeries were performed under isoflurane anesthesia (5% in O2
for induction and 2% in O2 for maintenance) in a stereotaxic frame
with the nose bar set at −4.5 mm (intramedial forebrain bundle
[MFB]) or −2.3 mm (intrastriatal). To induce Parkinsonism, rats
received a unilateral MFB lesion using 6-OHDA (12 μg in 3-μl 0.1%
ascorbate saline) at stereotaxic coordinates anterior–posterior
(AP) −4.0 mm, medial–lateral (ML) −1.3 mm (from bregma), and
dorsal–ventral (DV) −7.0 mm below dura. For transplant surgery, rats
received unilateral intrastriatal transplants in a volume of 3 μl of
hUC-MSCs alone (10,000 cells/μl; n = 10), collagen alone (n = 10),
collagen-encapsulated hUC-MSCs (10,000 cells/μl; n = 10) or saline
solution (n = 10) at stereotaxic coordinates AP 0.0, ML −3.7 mm
(from bregma), and DV −5.0 mm below dura (Figure 1). Injection
speed rate was set at 1 μl/min, and the needle remained in situ for
another 2 min to allow for diffusion. Animals were sacrificed 1 day
(n = 20) or 14 days (n = 20) after implantation by terminal anesthesia
and were transcardially transfused with 100-ml heparinized saline
solution. Brains were rapidly removed, snap frozen in liquid nitrogen,
and stored at −80 C until further analysis.
2.5 | Sample preparation for mass spectrometry
analysis
Coronal sections of the right striatum containing the implants, the
same area of the intact left hemisphere and the 6-OHDA-lesioned
area of the right hemisphere, were cut at a thickness of 100 μm in a
cryostat (Microm HM550; Thermo Fisher Scientific) and ground in
8-M urea in 10-mM Tris pH 8 buffer for protein extraction. Protein
concentration was determined with 2D-Quant kit (#80-6483-56; GE
Healthcare), and subsequently, 10 μg of total protein (5 μl) was
incubated with 2-μl 10-mM dithiothreitol for 30 min at room
temperature to reduce disulfide bonds. Thereafter, cysteine residues
were alkylated with 50-mM 2-chloroacetamide in 50-mM ammonium
bicarbonate (ABC) for 20 min at room temperature in the dark. Then
0.5 μg/μl of the endopeptidase LysC was added and incubated for 3 h
at room temperature. Samples were then diluted 4× with 50-mM
ABC and incubated overnight at room temperature with 1-μg
trypsin/50-μg total protein. Bond Elut C18 Omix tips (Agilent)
were used to desalt and concentrate the peptide mixtures prior to
LC–MS/MS measurements.
2.6 | Liquid chromatography—tandem mass
spectrometry
Measurements of each sample were performed using C18 reversed
phase liquid chromatography in combination with online tandem mass
F IGURE 1 Injection area. (a) Stereotaxic coordinates. In black, lesion in the medial forebrain bundle using 6-hydroxydopamine (AP: −4.0-mm
bregma). In grey, transplantation plane of collagen-encapsulated cells in the striatum (AP: 0.0-mm bregma). Both lesion and transplantation were
performed unilaterally at the right hemisphere. (b) Coronal view of the transplantation side. The dot represents the implant and the square the
dissected area. AP, anterior–posterior [Colour figure can be viewed at wileyonlinelibrary.com]
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spectrometry (LC–MS/MS) in data-dependent acquisition mode. Two
microliters of trypsin digested sample was loaded onto the trapping
column (Acclaim PepMap 100, 75 μm × 2 cm, nanoViper, 3-μm 100-Å
C18 particles; Thermo Fisher Scientific) using 0.1% formic acid at
7,000 nl/min for 3 min. Next, peptides were separated on a C18
reversed phase analytical column (Acclaim PepMap RSLC,
75 μm × 15 cm, nanoViper, 2-μm 100-Å C18 particles; Thermo Fisher
Scientific) at 40 C using a linear gradient of 5%–35% acetonitrile,
0.1% formic acid in 240 min at 600 nl/min. Measurements were
performed using a nanoflow ultra-high-pressure liquid chromatograph
(nano-Advance; Bruker Daltonics, USA) coupled online to an
orthogonal quadrupole time-of-flight mass spectrometer (maXis Plus;
Bruker Daltonics) via an electrospray ionization source (Captive
sprayer; Bruker Daltonics). The mass spectrometer was operated in
positive ion mode to acquire line spectra in the mass range of m/z
150–2,200. Data-dependent acquisition of MS/MS spectra (AutoMSn)
was performed using a 3-s duty cycle at 2-Hz acquisition rate for full
MS spectra and a variable number of MS/MS experiments. Precursor
ions within the range of m/z 400–1,400 with charge state z ≥ 2+ were
selected for MS/MS analysis with active exclusion enabled.
For the analysis of detected peptides of 6-OHDA-lesioned area
versus intact area, a 120-min gradient was used, instead of 240 min.
The rest of the settings were the same as described above.
2.7 | Database searches
Detected peptides were analyzed using MaxQuant software (v1.6.2.6)
and searched against the Rattus norvegicus database (SwissProt) with
added sequence of the known contaminant Bos Taurus Type I collagen
using the built-in Andromeda search engine. The decoy database used
for false discovery rate validation contained the reversed protein
sequences. Desired maximum false discovery rate at both peptide and
protein identification levels was set to 1%. MaxQuant MS/MS database
searches were performed with 10-ppm and 0.5-Da mass tolerance for
precursor ions and fragments ions, respectively. Carbamidomethylation
(at cysteine residues) was specified as fixed modification, whereas
deamidation (at asparagine and glutamine residues), acetylation (protein
N-terminus), and oxidation (at methionine residues) were selected as
variable modifications. Trypsin was selected as a specific enzyme, and a
maximum of two missed tryptic cleavages was accepted.
For the analysis of detected peptides of 6-OHDA-lesioned
area versus intact area, PEAKS® studio X software was using
identical settings as mentioned above for MaxQuant for MS/MS
database searches.
2.8 | Gene ontology and data analysis
Gene Ontology (GO) and pathway analysis were performed using
PANTHER Classification System (http://www.pantherdb.org).
Pearson's correlation between samples, principal component
analysis (PCA), one-way ANOVA with Fisher's least significant
difference (LSD) post hoc test, pairwise t-test with Bonferroni
correction, and volcano plots of the label-free quantification (LFQ) values
were performed using metaboanalyst (https://www.metaboanalyst.ca,
v4.0) and the R-programming platform (v3.5.3, The R Foundation for
Statistical Computing). An adjusted p value < .05 was considered as
statistically significant. The threshold for the fold change (FC) in the
volcano plot was set at 2.0.
3 | RESULTS
3.1 | Reproducibility and robustness of mass
spectrometry analysis
A total of 2,219 proteins were identified using shotgun proteomics of
dissected striatum samples. For 12 out of 49 samples, we observed
poor mass spectrometry signals. Replicate sample preparation and
measurements yielded identical results for these 12 samples that
were, thus, omitted from this study because of poor sample quality
(data not shown). Final number of samples in downstream data
analysis can be found inTable 1.
To assess the robustness and reproducibility of the proteomics
analysis, we calculated the coefficient of variation (CV) of the LFQ
values of biological replicates. In all cases, the intra-group CV was lower
than 15% (data not shown), which is consistent with good analytical
accuracy and minimal biological variation. Then, we created a matrix of
Pearson's correlations of the LFQ values; all the proteins identified in
one sample were correlated with all the proteins found in another
one. For all comparisons, a correlation higher than .88 was obtained,
indicating high robustness and reproducibility of the technique.
Moreover, this high correlation factor means there is close similarity
between samples, indicating similar protein expression profiles in all
samples (Figure 2a,b). Detailed analysis of the sample with the lowest
correlation coefficient (r = .88), which is still high (Figure 2c), revealed
that this was caused by higher LFQ values of blood-derived proteins,
mainly serum albumin, hemoglobin, and murinoglobulin. Indeed, this
sample showed significant visual blood contamination at dissection time.
Because of power and lack of effect of those blood proteins in the rest
of the proteins, this sample was included in the analysis.
TABLE 1 Number of rats per group after liquid chromatography tandem mass spectrometry
Lesion + vehicle Lesion + collagen Lesion + hUC-MSCs Lesion + hUC-MSCs + collagen Intact
Day 1 4 3 4 3 3
Day 14 5 4 4 4 4
Note. Only good quality data were included in the downstream data analysis. Initially, each group contained five animals, except the lesion + collagen group
that had n = 4 because one of the rats died during surgery.
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3.2 | Effects of biomaterials and hUC-MSCs on
striatal protein expression
We compared the host tissue response in protein expression between
treatment groups (intact, sham, hUC-MSCs alone, collagen alone, or
collagen-encapsulated hUC-MSCs) and time-window after implantation
(1 or 14 days). We analyzed large regions of striatum to map the
expected dramatic changes in the brain proteome. The PCA plot
showed close proximity of the scores for all samples, which shows that
the majority of consistent variation in protein expression is not related
to group differences that is underlined by the low percentage of
variance explained by principal components PC1 (9.2%) and PC2
(6.7%) (Figure 3). One-way ANOVA with post hoc testing was
performed on the 2,219 LFQ values to explore whether there was
a differential host tissue response between treatment groups.
No significant difference in expression of proteins was detected
(Figure 4a). We also performed pairwise comparisons of individual
proteins using t-tests and volcano plots to identify statistically and
biologically significant changes (example shown in Figure 4b). The
23 paired group comparisons showed no differences when multiple
test correction was applied (data not shown).
A GO enrichment analysis could not be performed on host tissue
responses as no statistically different proteins were identified
between groups. However, we did GO studies and pathway analysis
of the whole protein set of identified proteins (data not shown). All
identified pathways are related to brain specific processes, as well as
F IGURE 2 Pearson's correlations. (a) Matrix of Pearson's correlations across all samples in all treatment groups. All samples presented similar
expression profiles (r > .88). (b) Example of the correlation of all 2,219 identified proteins individually for the highest 1-to-1 correlation that was
observed (r = .99). (c) Example of the correlation of all 2,219 identified proteins individually for the lowest 1-to-1 correlation that was observed
(r = .88). Blood-derived proteins were observed in one sample only, a tissue that presented a red bloody area at dissection time and resulted in
contamination with blood-derived proteins in the lysate. LFQ, label free quantification [Colour figure can be viewed at wileyonlinelibrary.com]
F IGURE 3 Principal component analysis of protein expression
profiles of rat striatum indicating variations between intact brain and
implanted brains with collagen scaffold, human umbilical cord
mesenchymal stem cells (hUC-MSCs), or collagen-encapsulated
hUC-MSCs at either 1 or 14 days after implantation. Similar
characteristics between groups can be observed. PC, principal
component [Colour figure can be viewed at wileyonlinelibrary.com]
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metabolic and inflammatory processes, confirming correct protein
annotation of our identified proteomes that could have been involved
in the expected tissue responses to the implant.
3.3 | Protein expression profiles between intact area
and 6-OHDA lesion area
The lack of differences between treatment conditions could be
explained by a lack of treatment effect or by localization of the effect
to a small region with masking of differential proteins by other
proteins of the dissected area. To investigate this, we compared the
proteomic profiles of the intact striatal area of the brain with the area
injured with 6-OHDA injection. We hypothesized that, if no
differences between these two different areas could be detected, it
would indicate that the effects were too local and, thus, could not
be detected.
We analyzed four intact striatal sections of the brain hemisphere
and four MFB 6-OHDA-lesioned ones. One intact and one lesioned
area showed poor quality of the mass spectrometry signals and,
thus, were not used in the downstream data analysis. A total of
551 proteins were identified in this analysis. The lower number of
identified proteins is due to the shorter gradient used during the
chromatography (120 vs. 240 min). Pearson's correlation between
samples showed high correlation between samples (r > .89;
Figure 5). Group comparison using t-test as well as volcano plot
analysis with post hoc testing showed no significant differences
between groups (Figure 6), indicating that the expected effects are
too local to be detected.
3.4 | Viability of hUC-MSCs into the collagen
hydrogel
Encapsulation and implantation of 3 μl of stem cells (10,000 cells/μl)
was previously described with positive outcomes: diminished the host
brain's response and increased survival and reinnervation of the
implanted cells (Hoban et al., 2013; Moriarty et al., 2017; Moriarty
et al., 2019). However, in none of these studies, hUC-MSCs were
used. Therefore, we considered the possibility that hUC-MSCs
survival is limited by collagen encapsulation at the concentrations
described, and as a result, no effects in our study could be observed.
We observed that the viability of high concentrated cells (10,000
cells/μl) dropped to 22.3 ± 31.6% upon encapsulation, whereas the
viability of low concentrated cells (2,500 cells/μl) was around
67.6 ± 9.7%, similar to the viability obtained in 2D cultures
(68.1 ± 14.1). The results suggest that the cells might not have
survived long time inside the hydrogel after implantation into the rat's
striatum and, thus, caused non-effect on the host proteome.
F IGURE 4 Treatment group comparisons. (a) One-way ANOVA with post hoc test. The log 10 of the non-corrected p value for all quantified
proteins was plotted on the y-axis and each protein at the x-axis. No significant different protein levels between groups were found. The post hoc
Fisher's least significant difference adjusted p value cutoff was .05. (b) Example of a volcano plot (intact brain Day 1 vs. implanted collagen-
encapsulated hUC-MSC Day 1). Volcano plots connect mathematical and biological differences. At the y-axis, the negative logarithm base 10 of
the non-corrected p value, −log 10(non-corrected p value), was plotted. Threshold was set at p value = .05, which corresponds to a value of 1.3
after log transformation. At the x-axis, the logarithm base 2 of the fold change, log2(FC), was plotted and the threshold was set at 2, which
corresponds to a log2(FC) of 1. Note that the graph shows the non-corrected p value and not the adjusted p value after post hoc test. After post
hoc, no significant differences on expression profiles were observed
F IGURE 5 Pearson's correlation matrix between lesioned and
intact area (I). High correlations between samples were observed
(r > .89) [Colour figure can be viewed at wileyonlinelibrary.com]
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4 | DISCUSSION
The present study is an explorative assessment to the host proteomic
changes following implantation of collagen-encapsulated hUC-MSCs
into the striatum of the 6-OHDA rat model of PD by using
LC–MS/MS. Results showed high robustness and reproducibility of
mass spectrometry analyses with low variation between biological
replicates. Group comparison between treatment conditions and
time post-treatment showed no significant differences in protein
expression levels between groups. This result was unexpected as we
hypothesized that collagen-encapsulated hUC-MSCs would produce
widespread changes in the host tissue. Based on previous studies
(Hoban et al., 2013), we expected that 24 h after implantation bovine
collagen and increased levels of inflammation-related proteins would
be detected, which would have normalized after 14 days, a period
during which the level of trophic factors and other proteins involved
in biological processes would have changed. Previous similar studies
on 6-OHDA rat models implanted with collagen-encapsulated ventral
mesencephalic (VM) cells in combination with glial cell line-derived
neurotrophic factor (GDNF) loaded into the hydrogel observed
improvement of rat behavior, reduction of microgliosis and
astrogliosis, and an increase in GDNF (Moriarty et al., 2017; Moriarty
et al., 2019). This is in contrast to the findings in our study and
might be due to the use of hUC-MSCs instead of VM cells, the lack
of supportive GDNF and/or the analytical approach. We used
high-throughput mass spectrometry for proteomic profiling to get a
broad impression of proteomic changes, whereas others used
immunohistochemistry to analyze specific markers of microgliosis,
astrogliosis, and GDNF.
We used hUC-MSCs instead of another type of stem cell because
hUC-MSCs are largely available, easy to obtain and to expand, raise
fewer ethical concerns, are non-immunogenic, and release several
anti-inflammatory proteins and key neurotrophic factors. Specifically,
hUC-MSCs secrete large amounts of GDNF, which is specifically
beneficial for dopaminergic neurons (El Omar et al., 2014; Hass
et al., 2011). hUC-MSCs also present benefits in comparison with
bone marrow MSCs (BM-MSCs): hUC-MSCs weakly express
HLA-ABC (less immunogenic), grow faster because of the younger
origin, and have a higher differentiation potential (El Omar
et al., 2014; Hass et al., 2011). Some scientists in the field consider
hUC-MSCs not to be good candidates for brain regenerative therapy
because of their limited potential to differentiate into neurons
(Barker, Drouin-Ouellet, & Parmar, 2015; Stoker & Barker, 2018).
However, preclinical studies with cell models and rat models of PD
yielded beneficial effects when using hUC-MSCs as a treatment for
PD (Liu et al., 2014; Mathieu, Roca, Gamba, Del Pozo, & Pitossi, 2012;
Xiong et al., 2010), probably because of their valuable secretome
(El Omar et al., 2014; Teixeira et al., 2017). To date, there is one
ongoing clinical trial in humans using hUC-MSCs in PD patients
(NCT03550183; https://clinicaltrials.gov/).
The encapsulation and implantation procedures that we
followed were previously described with positive outcomes (Hoban
et al., 2013; Moriarty et al., 2017; Moriarty et al., 2019). However,
there were two main differences. First, hUC-MSCs have not been
used before, but rat dopamine-derived VM cells or rat BM-MSCs
were used, which showed good cell viability. In these studies,
cell viability was assessed 1 day after encapsulation. It might be
possible that survival is cell-type dependent or that hUC-MSCs
survival overtime is more limited by collagen encapsulation than
previously used stem cell types. To test this hypothesis, we
performed an in vitro study, in which two different concentrations
of cells were encapsulated into collagen hydrogel for 5 days. We
observed that viability of encapsulated cells decreased with
higher concentration of cells. Thus, viability of the cells might have
influenced our results. However, more detailed cell survival analysis
should be performed to provide a more definite answer. Second, in
previous experiments, GDNF-overexpressing cells were used, or the
scaffold was loaded with GDNF and cells. The elevated presence
of GDNF yielded a higher reinnervation, better behavior outcome,
and lower immune response in comparison with the encapsulated
cells without GDNF. The protective and supportive role of GDNF
for dopaminergic neurons has already been reported in several
F IGURE 6 Group comparison. (a) T-test with Bonferroni post hoc test. The logarithm base 10 of the non-corrected p value for all identified
proteins was plotted on the y-axis. No significant different protein levels were found. Note that the adjusted p values after post hoc test are not
plotted. (b) Volcano plot. On the y-axis, the logarithm base 10 of the non-corrected p values are plotted at a threshold of .5, corresponding to a
value of 1.3 after log transformation (horizontal line). On the x-axis, the logarithm base 2 of the fold change (FC) is plotted with a threshold set at
2.0, which corresponds to 1 after log transformation (vertical lines). Note that the graph shows the non-corrected p value and not the adjusted p
value after post hoc test. After post hoc, no significant differences on expression profile were observed
SANTAELLA ET AL. 1083
studies (Meka et al., 2015; Yasuhara et al., 2017). Thus, probably
hUC-MSCs should overexpress or be co-encapsulated with GDNF
to potentiate their therapeutic effects, which is supported by the
positive outcome of a study in which hUC-MSCs overexpressing
hepatocyte growth factor (HGF), a survival factor for motor
neurons, were used to treat a cell model of PD (Liu et al., 2014). In
this study, we did not load the scaffolds with GDNF because
we thought that the normal expression of GDNF by hUC-MSC
would be enough.
However, we believe that the main two explanations for the
lack of differences in protein expression levels in the present study
are the following: (a) there may be no effects strong enough to be
detected using shotgun proteomics and (b) the relative large
dissected area in comparison with the small area of implantation
diluted the effects. This second explanation is corroborated by the
finding that also no differences were observed between intact area
(no surgery) and lesion area (6-OHDA injection). Surgical procedures
activate the immune response and cause changes in the surrounding
area, and 6-OHDA injection causes the death of dopaminergic
neurons. In LC–MS/MS, the detection of low-abundant proteins is
hampered by the presence of high-abundant proteins (Qian, Jacobs,
Liu, Camp, & Smith, 2006). Consequently, common and abundant
proteins from the cell membrane, extracellular matrix, and organelles
have high probability to be detected and to mask the low-abundant
proteins, such as trophic factors, cytokines, and chemokines. This
masking effect might be intensified by the local effects of the
transplant, which affects a relatively small area of the brain in
comparison with the rest of the hemisphere. Immunohistochemistry
studies showed that transplantation may have a radial effect
extending up to 200–250 μm away from the site of injection
(Moriarty et al., 2017). Also, literature search revealed that similar
studies using shotgun mass spectrometry in rat brains focused on
larger areas of interest with bigger effects, pooled several brains,
and/or coupled mass spectrometry to a previous microdissection of
the tissue or protein separation techniques (Campos-Martorell
et al., 2014; Gellen et al., 2017; Quanico, Franck, Wisztorski, Salzet, &
Fournier, 2017; Zhang et al., 2018).
Given the lack of widespread differences of protein expression
levels, other techniques may be better suited to unravel the proteomic
changes after implantation. Laser capture microdissection (LCM) in
combination with LC–MS/MS or mass spectrometry imaging (MSI)
may be alternatives. Both techniques present advantages but also
limitations. LCM has already been used to isolate brain cell
populations for gene and protein expression analysis (Fustin,
Karakawa, & Okamura, 2017; Sussulini & Becker, 2015). However, in
our experimental setting, we would need to dissect a donut-shaped
tissue area to be able to differentiate the host tissue response
from the transplanted cells, which would be complicated and time
consuming. MSI uses the combination of molecular mass analysis
and spatial information, providing visualization of molecules directly
from a complex tissue surface. MSI has become a workhorse for
proteomic and peptidomic studies (Huber et al., 2018; Norris &
Caprioli, 2013). However, MSI presents some drawbacks: the spatial
resolution is lost due to on slide tryptic digestion, and the proteome
coverage is limited to a few hundred proteins. Nonetheless, promising
advances have been made to study the proteome of murine brains
(Heijs et al., 2015; Huber et al., 2018; Stoeckli, Staab, Staufenbiel,
Wiederhold, & Signor, 2002).
In summary, we intended to determine the proteomic changes in
the striatum of the 6-OHDA PD rat model after implantation of
collagen hydrogel-encapsulated hUC-MSCs. Our results confirmed
the high robustness and reproducibility of our analysis but could not
determine differences between groups. We believe that the lack of
differences between groups is because, if there is an effect, it is
neither strong nor widespread. For future experiments, we suggest
that LCM combined with LC–MS/MS or MALDI imaging techniques,
despite their own disadvantages, may yield a more detailed insight
into the host tissue proteomic response to the transplanted
encapsulated cells in order to be able to assess the efficacy and
safety of collagen-encapsulated hUC-MSCs as a disease modifying
therapy for PD.
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